Open AccessDNA Methylation Inhibitors in Cancer Therapy: The Immunity Dimension
Author(s) -
Jonathan D. Licht
Publication year - 2015
Publication title -
cell
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 26.304
H-Index - 776
eISSN - 1097-4172
pISSN - 0092-8674
DOI - 10.1016/j.cell.2015.08.005
Subject(s) - biology , dna , dna methylation , endogeny , endogenous retrovirus , immunity , cancer research , cancer , epigenetics , immunology , computational biology , genetics , gene , immune system , genome , gene expression , biochemistry
DNA demethylating agents are approved for some blood malignancies and are under active investigation in solid tumors, but how these drugs work has remained unclear. In this issue of Cell, two groups show that these agents activate a toxic cellular antiviral program through transcriptional activation of endogenous retroviral sequences.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom